ResMed Statistics

Total Valuation

ResMed has a market cap or net worth of AUD 55.68 billion. The enterprise value is 56.33 billion.

Market Cap	55.68B
Enterprise Value	56.33B

Important Dates

The next estimated earnings date is Thursday, January 23, 2025.

Earnings Date	Jan 23, 2025
Ex-Dividend Date	Nov 6, 2024

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+0.02%
Shares Change (QoQ)	+0.04%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	145.80M

Valuation Ratios

The trailing PE ratio is 34.69.

PE Ratio	34.69
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	21.09
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 21.00, with an EV/FCF ratio of 28.86.

EV / Earnings	35.09
EV / Sales	7.33
EV / EBITDA	21.00
EV / EBIT	23.71
EV / FCF	28.86

Financial Position

The company has a current ratio of 2.92, with a Debt / Equity ratio of 0.16.

Current Ratio	2.92
Quick Ratio	1.44
Debt / Equity	0.16
Debt / EBITDA	0.51
Debt / FCF	0.63
Interest Coverage	40.98

Financial Efficiency

Return on equity (ROE) is 23.56% and return on invested capital (ROIC) is 15.72%.

Return on Equity (ROE)	23.56%
Return on Assets (ROA)	13.27%
Return on Capital (ROIC)	15.72%
Revenue Per Employee	694,773
Profits Per Employee	160,833
Employee Count	9,980
Asset Turnover	0.69
Inventory Turnover	1.82

Taxes

In the past 12 months, ResMed has paid 335.18 million in taxes.

Income Tax	335.18M
Effective Tax Rate	18.95%

Stock Price Statistics

The stock price has increased by +44.01% in the last 52 weeks. The beta is 0.69, so ResMed's price volatility has been lower than the market average.

Beta (5Y)	0.69
52-Week Price Change	+44.01%
50-Day Moving Average	37.57
200-Day Moving Average	33.76
Relative Strength Index (RSI)	41.20
Average Volume (20 Days)	1,171,114

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	7.94

Income Statement

In the last 12 months, ResMed had revenue of AUD 6.93 billion and earned 1.61 billion in profits. Earnings per share was 10.87.

Revenue	6.93B
Gross Profit	4.04B
Operating Income	2.14B
Pretax Income	1.98B
Net Income	1.61B
EBITDA	2.35B
EBIT	2.14B
Earnings Per Share (EPS)	10.87

Full Income Statement

Balance Sheet

The company has 638.33 million in cash and 1.23 billion in debt, giving a net cash position of -587.98 million.

Cash & Cash Equivalents	638.33M
Total Debt	1.23B
Net Cash	-587.98M
Net Cash Per Share	n/a
Equity (Book Value)	7.49B
Book Value Per Share	51.05
Working Capital	2.51B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.08 billion and capital expenditures -125.86 million, giving a free cash flow of 1.95 billion.

Operating Cash Flow	2.08B
Capital Expenditures	-125.86M
Free Cash Flow	1.95B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 58.33%, with operating and profit margins of 30.84% and 23.15%.

Gross Margin	58.33%
Operating Margin	30.84%
Pretax Margin	28.62%
Profit Margin	23.15%
EBITDA Margin	33.95%
EBIT Margin	30.84%
FCF Margin	28.15%

Dividends & Yields

This stock pays an annual dividend of 0.46, which amounts to a dividend yield of 1.24%.

Dividend Per Share	0.46
Dividend Yield	1.24%
Dividend Growth (YoY)	-65.43%
Years of Dividend Growth	2
Payout Ratio	26.02%
Buyback Yield	-0.02%
Shareholder Yield	1.22%
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Stock Splits

The last stock split was on August 12, 2010. It was a forward split with a ratio of 2.

Last Split Date	Aug 12, 2010
Split Type	Forward
Split Ratio	2

Scores

ResMed has an Altman Z-Score of 10.95 and a Piotroski F-Score of 5.

Altman Z-Score	10.95
Piotroski F-Score	5